Supplementary information

Table S1: List of primers used in the study: Primers used for the development of the GPCR–NanoBiT[®] fusion constructs. a: Forward (F) and Reverse (R) primers $(5' \rightarrow 3')$ with restriction enzyme sites (underlined). b: Annealing temperature. c: Restriction enzyme.

	Primers $(5' \rightarrow 3')^{a}$	Restriction site	Tm (°C) ^b	Fusion construct
F	TAG <u>AAGCTT</u> ATGGATCCACTGAATCTGTCC	HindIII, EcoRI	60	D2LR-LgBiT
R	AGTATA <u>GAATTC</u> TTGCAGTGGAGGATCTTC AGG			
F	TAG <u>AAGCTT</u> ATGGATCCACTGAATCTGTCC	<i>Hin</i> dIII, EcoRI	60	D2LR-SmBiT
R	AGTATA <u>GAATTC</u> TTGCAGTGGAGGATCTTC AGG			
F	TAG <u>AAGCTT</u> ATGGACAGCAGCGCTGCC	HindIII, XhoI	60	MOR-LgBiT
R	GTAG <u>CTCGAG</u> TTGGGCAACGGAGCAGTTTC			
F	TAG <u>AAGCTT</u> ATGGACAGCAGCGCTGCC	HindIII, XhoI	60	MOR-SmBiT
R	GTAG <u>CTCGAG</u> TTGGGCAACGGAGCAGTTTC			

Table S2: Overview of the functionality of constructs used in the study using various assays and agonists.

Construct	Dopamine	DAMGO	Assay used
D2LR-EGFP	+	_	Receptor internalization
MOR-YFP	NA	+	Receptor internalization
D _{2L} R-LgBiT	+	NA	Calcium release
D2LR-SmBiT	+	NA	Calcium release
MOR-LgBiT	NA	+	Calcium release
MOR-SmBiT	NA	+	Calcium release
Untransfected HeLa cells	_	_	Calcium release

HeLa cells were transfected with the above-mentioned constructs. After 48 h, functionality of the tagged receptors was evaluated by monitoring their capacity to internalize or stimulate calcium release upon stimulation with their respective agonists. "+": indicates calcium release or receptor internalization observed; "-": no change observed; NA: not analyzed.





Figure S1: Analysis of D₂sR receptor dimerization with MOR using co-immunoprecipitation. HEK 293T cells were transiently transfected with pFLAG-D₂sR, pMOR-YFP or both. After 48 h, the cells were lysed and an aliquot was loaded onto SDS-PAGE followed by immunoblotting with anti-D₂R or anti-GFP. The rest of the lysates was subjected to IP with anti-FLAG. Co-immunoprecipitation of D₂sR and MOR was detected by immunoblotting with A) anti-GFP and B) anti-D₂R.